TG Therapeutics Inc (NASDAQ: TGTX) has reported E.P.S. of $0.03 for its third fiscal quarter (ending September 30) versus $0.80 for the same period a year ago — a decline of -96%. For the latest four quarters through September 30, E.P.S. were $-0.10 versus $-0.20 for the same period a year ago — a decline of -50%.
Recent Price Action
TG Therapeutics Inc (NASDAQ: TGTX) stock closed at $24.36 on 11/4/24 after a large decline of -9.4%. Moreover, exceptionally high trading volume at 268% of normal accompanied the decline. The stock has risen 4.3% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
TGTX is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
TG Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. TG Therapeutics has a very high Appreciation Score of 92 and a very high Power Rating of 97, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment